Physician profile
Shane A Grace
NPI 1033527684
$4,521.42
in general payments reported to CMS, 2019-2025
24 companies · $528 in 2025
The $528 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $353 · 2022: $1,122 · 2023: $1,491 · 2024: $1,027 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,946 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,946.17 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $825.96 | 2021-2025 | |
| Janssen Biotech, INC. | $646.41 | 2021-2025 | Tremfya |
| Dermavant Sciences, INC. | $409.30 | 2023-2024 | Vtama |
| Lilly USA, LLC | $315.52 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $314.58 | 2021-2024 | |
| Ucb, INC. | $281.69 | 2022-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $258.70 | 2022-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $146.04 | 2021 | |
| Genzyme Corporation | $142.41 | 2021-2024 | |
| Amgen INC. | $140.34 | 2022-2023 | Otezla |
| Galderma Laboratories, L.P. | $136.71 | 2022-2024 | Aklief, Epsolay, Oracea |
| Pfizer INC. | $127.57 | 2021-2025 | |
| Strata Skin Sciences, INC. | $124.47 | 2023-2025 | Xtrac |
| Leo Pharma INC. | $120.28 | 2021-2024 | Adbry |
| Organon LLC | $117.86 | 2023-2025 | Vtama, Hadlima |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $84.04 | 2022-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Sun Pharmaceutical Industries INC. | $83.76 | 2023-2024 | Winlevi |
| Incyte Corporation | $54.93 | 2022 | |
| Almirall LLC | $54.52 | 2022-2024 | Klisyri |
| Kerecis Limited | $50.03 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Mayne Pharma Commercial LLC | $31.67 | 2022-2023 | |
| Arcutis Biotherapeutics, INC. | $20.84 | 2024 | Zoryve |
| Epi Health, LLC | $18.09 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $15.70 | 2023 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shane Grace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.